Psyence Biomedical (PBM) Income towards Parent Company (2023 - 2025)

Psyence Biomedical's Income towards Parent Company history runs 3 years deep, the most recent figure standing at -$1.5 million for Q3 2025.

• On a quarterly basis, Income towards Parent Company fell 1163.79% year-over-year to -$1.5 million in Q3 2025; TTM through Mar 2026 was -$1.4 million, a 710.6% decrease from a year earlier, with the FY2026 full-year figure at -$6.2 million, down 70.34% from the prior year.
• Income towards Parent Company eased to -$1.5 million in Q3 2025 per PBM's latest filing, from $141473.0 in the prior quarter.
• Across five years, Income towards Parent Company topped out at $141473.0 in Q3 2024 and bottomed at -$3.2 million in Q1 2023.
• The 3-year median for Income towards Parent Company is -$907329.5 (2023), against an average of -$1.2 million.
• Across the five-year window, Income towards Parent Company soared 145.68% in 2024 and plunged 1163.79% in 2025, its largest moves.
• Year by year, Income towards Parent Company stood at -$309682.0 in 2023, then surged by 145.68% to $141473.0 in 2024, then plunged by 1163.79% to -$1.5 million in 2025.
• Per Business Quant, the three latest PBM Income towards Parent Company figures stand at -$1.5 million (Q3 2025), $141473.0 (Q3 2024), and -$309682.0 (Q3 2023).